
Tricida TCDA
Quartalsbericht 2022-Q3
hinzugefügt 14.11.2022
Land |
|
IPO-Jahr |
2018 |
Branche |
Arzneimittelhersteller |
Börse |
NASDAQ GLOBALSPB |
Anteile |
51.3 M |
Marktkapitalisierung |
$ 3.25 M |
EBITDA (LTM) |
$ -113 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
-2.23 |
Andere Aktien der Branche "Arzneimittelhersteller"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | Nasdaq Global Market | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | Nasdaq Capital Market | ||
|
Canopy Growth Corporation
CGC
|
$ 1.07 | -0.47 % | $ 115 M | Nasdaq Global Select Market | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | Nasdaq Global Market,SPB | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | Nasdaq Capital Market | ||
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | Nasdaq Global Market | ||
|
Cronos Group
CRON
|
$ 2.62 | -0.57 % | $ 1.36 B | Nasdaq Global Market | ||
|
Avadel Pharmaceuticals plc
AVDL
|
- | - | $ 2.06 B | Nasdaq Global Select Market | ||
|
China Pharma Holdings
CPHI
|
$ 0.55 | -0.97 % | $ 9.61 M | NYSE American | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 4.5 | -7.02 % | $ 63.3 M | Nasdaq Global Select Market | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | Nasdaq Global Select Market | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | NYSE | ||
|
Aurora Cannabis
ACB
|
$ 3.52 | -5.26 % | $ 86.3 M | NYSE | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | Nasdaq Global Select Market | ||
|
Harrow Health
HROW
|
$ 38.95 | -27.32 % | $ 1.43 B | Nasdaq Global Market | ||
|
Emergent BioSolutions
EBS
|
$ 8.87 | -1.33 % | $ 454 M | NYSE,SPB | ||
|
Assertio Holdings
ASRT
|
$ 11.92 | 1.24 % | $ 847 M | Nasdaq Capital Market | ||
|
Evolus
EOLS
|
$ 4.21 | -1.86 % | $ 261 M | Nasdaq Global Market | ||
|
Bausch Health Companies
BHC
|
$ 5.77 | -3.11 % | $ 2.11 B | NYSE | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | NYSE | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | NYSE,SPB | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | Nasdaq Capital Market | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | Nasdaq Global Market,SPB | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | Nasdaq Global Select Market,SPB | ||
|
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | Nasdaq Capital Market | ||
|
OrganiGram Holdings
OGI
|
$ 1.38 | -3.17 % | $ 402 M | Nasdaq Global Select Market | ||
|
Organogenesis Holdings
ORGO
|
$ 2.86 | -4.67 % | $ 377 M | Nasdaq Capital Market | ||
|
Perrigo Company plc
PRGO
|
$ 11.38 | -7.97 % | $ 1.58 B | NYSE | ||
|
Rockwell Medical
RMTI
|
$ 0.9 | 0.37 % | $ 21 M | Nasdaq Global Market | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | Nasdaq Global Select Market | ||
|
Sundial Growers
SNDL
|
$ 1.53 | 0.33 % | $ 3.37 M | Nasdaq Global Select Market | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Nasdaq Global Select Market | ||
|
TherapeuticsMD
TXMD
|
$ 2.26 | 1.0 % | $ 23.6 M | Nasdaq Global Select Market | ||
|
Pacira BioSciences
PCRX
|
$ 22.06 | 3.67 % | $ 1.02 B | Nasdaq Global Select Market,SPB | ||
|
Veru
VERU
|
$ 2.54 | -3.05 % | $ 343 M | Nasdaq Capital Market | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | Nasdaq Global Select Market,SPB | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | Nasdaq Global Select Market | ||
|
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | Nasdaq Capital Market | ||
|
Viatris
VTRS
|
$ 15.09 | -3.89 % | $ 18.1 B | Nasdaq Global Select Market,SPB | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | Nasdaq Capital Market | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | Nasdaq Global Market | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | Nasdaq Global Select Market | ||
|
Relmada Therapeutics
RLMD
|
$ 4.67 | -3.51 % | $ 141 M | Nasdaq Global Select Market,SPB | ||
|
cbdMD
YCBD
|
$ 0.79 | -2.48 % | $ 3.41 M | NYSE American | ||
|
SCYNEXIS
SCYX
|
$ 0.73 | -2.19 % | $ 34.9 M | Nasdaq Global Select Market | ||
|
Solid Biosciences
SLDB
|
$ 5.99 | -3.47 % | $ 244 M | Nasdaq Global Select Market,SPB | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 2.76 | -2.66 % | $ 3.43 M | Nasdaq Capital Market | ||
|
Tilray
TLRY
|
$ 7.37 | -2.97 % | $ 4.55 B | Nasdaq Global Select Market | ||
|
Zynerba Pharmaceuticals
ZYNE
|
- | - | $ 55.5 M | Nasdaq Global Market,SPB |